Thus, strategies that can help to overcome tumor-intrinsic acquired resistance to ICI-based monotherapy or dual therapies include combinations with chemotherapy, oncogene-targeted therapies, antiangiogenic therapies, immunostimulatory antibodies (e.g., CD27 or CD40), adoptive T or NK cell transfer, and cancer vaccination, as discussed in Section 3.2, Section 3.3, Section 3.4 and Section 3.5. The gene discussed is CD40; the disease is cancer.